FrancophonIA/ELRC3.0 huggingface dataset:
English: Adverse reactions by system organ class and frequency Infections and infestations
Croatian: Nuspojave prema klasifikaciji organskih sustava i učestalosti pojavljivanja Infekcije i infestacije često infekcije mokraćnih puteva
English: • Decreased levels of platelets (thrombocytopenia)
Croatian: • smanjena razina trombocita (trombocitopenija)
English: Two Phase 3 clinical studies were completed in a total of 851 postmenopausal women with advanced breast cancer who had disease recurrence on or after adjuvant endocrine therapy or progression following endocrine therapy for advanced disease.
Croatian: Završena su dva klinička ispitivanja faze 3 s ukupno 851 ženom u postmenopauzi s uznapredovalim rakom dojke u kojih se bolest ponovno javila tijekom ili nakon adjuvantnog endokrinog liječenja ili je došlo do progresije nakon endokrinog liječenja uznapredovale bolesti.
English: No patients reported events that were CTCAE Grade ≥3 or that required a dose reduction, dose interruption, or discontinued treatment due to these adverse reactions.
Croatian: Common Terminology Criteria for Adverse Events, CTCAE) niti događaj koji je zahtijevao smanjenje doze, privremeni prekid primjene ili obustavu liječenja zbog tih nuspojava.
English: Uncommon Febrile neutropenia Metabolism and nutrition disorders Very common Decreased appetite Nervous system disorders Common Dysgeusia Eye disorders Common Lacrimation increased Vision blurred Dry eye Respiratory, thoracic and mediastinal disorders Common Epistaxis Gastrointestinal disorders Very common Nausea Stomatitis Diarrhoea Vomiting Skin and subcutaneous tissue disorders Very common Alopecia Rash Common Dry skin General disorders and administration site conditions Very common Fatigue Pyrexia Common Asthenia Investigations Common AST increased ALT increased
Croatian: Manje često febrilna neutropenija Poremećaji metabolizma i prehrane Vrlo često smanjen tek Poremećaji živčanog sustava Često disgeuzija Poremećaji oka Često pojačano suzenje zamagljen vid suhoća oka Poremećaji dišnog sustava, prsišta i sredoprsja Često epistaksa
English: The term injection site reactions does not include the terms injection site haemorrhage, injection site haematoma, sciatica, neuralgia and neuropathy peripheral.
Croatian: Izraz reakcije na mjestu injekcije ne obuhvaća krvarenje na mjestu injekcije niti hematom na mjestu injekcije, išijas, neuralgiju, i perifernu neuropatiju.
English: Faslodex contains 10% w/v ethanol (alcohol), i.e. up to 500 mg per injection, equivalent to 10 ml beer or 4 ml wine.
Croatian: Faslodex sadrži 10% m/V etanola (alkohol), odnosno do 500 mg po injekciji, što odgovara 10 ml piva ili 4 ml vina.
English: Do not use Faslodex: - if you are allergic to fulvestrant or to any of the other ingredients of this medicine (listed in section 6) - if you are pregnant or breast-feeding - if you have severe liver problems
Croatian: Nemojte primjenjivati Faslodex - ako ste alergični na fulvestrant ili neki drugi sastojak ovog lijeka (naveden u dijelu 6. „Što
English: Mechanism of action and pharmacodynamic effects Fulvestrant is a competitive estrogen receptor (ER) antagonist with an affinity comparable to estradiol.
Croatian: Fulvestrant je kompetitivni antagonist estrogenskih receptora (ER), čiji je afinitet usporediv s estradiolom.
English: One pre-filled syringe contains 250 mg fulvestrant in 5 ml solution.
Croatian: Jedna napunjena štrcaljka sadržava 250 mg fulvestranta u 5 ml otopine.
English: • Back pain*
Croatian: • bol u leđima*
English: • in combination with palbociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy (see section 5.1).
Croatian: • u kombinaciji s palbociklibom za liječenje lokalno uznapredovalog ili metastatskog raka dojke koji je pozitivan na hormonski receptor (HR) i negativan na receptor humanog epidermalnog faktora rasta 2 (engl. human epidermal growth factor receptor 2, HER2) u žena koje su prethodno primale endokrinu terapiju (vidjeti dio 5.1).
English: Kaplan-Meier plot of progression-free survival (investigator assessment, intent-to-treat population) - PALOMA3 study
Croatian: Slika 2. Kaplan-Meierova krivulja preživljenja bez progresije bolesti (ocjena ispitivača, populacija predviđena za liječenje) - ispitivanje PALOMA3
English: The study met its primary endpoint of prolonging investigator-assessed PFS at the interim analysis conducted on 82% of the planned PFS events; the results crossed the pre-specified Haybittle-Peto efficacy boundary (α=0.00135), demonstrating a statistically significant prolongation in PFS and a clinically meaningful treatment effect.
Croatian: Rezultati su nadmašili unaprijed specificiranu granicu djelotvornosti prema Haybittleu i Petou (α=0,00135) te pokazali statistički značajno produljenje PFS-a i klinički važan terapijski učinak.
English: A total of 521 pre/peri- and postmenopausal women who had progressed on or within 12 months from completion of adjuvant endocrine therapy on or within 1 month from prior endocrine therapy for advanced disease, were randomised 2:1 to Faslodex plus palbociclib or Faslodex plus placebo and stratified by documented sensitivity to prior hormonal therapy, menopausal status at study entry (pre/peri- versus postmenopausal), and presence of visceral metastases.
Croatian: Ukupno je 521 žena u predmenopauzi/perimenopauzi i postmenopauzi kojoj je bolest progredirala tijekom ili unutar 12 mjeseci od završetka adjuvantne endokrine terapije odnosno tijekom ili unutar mjesec dana od završetka endokrine terapije za uznapredovalu bolest randomiziranu u omjeru 2:1 za liječenje kombinacijom lijeka Faslodex i palbocikliba ili kombinacijom lijeka Faslodex i placeba.
English: • in combination with palbociclib to treat women with a type of breast cancer called hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, that is locally advanced or has spread to other parts of the body (metastatic).
Croatian: • u kombinaciji s palbociklibom, za liječenje žena s jednom vrstom raka dojke koji se zove rak dojke pozitivan na hormonski receptor i negativan na receptor ljudskog epidermalnog faktora rasta 2, a koji je lokalno uznapredovao ili se proširio na druge dijelove tijela (metastatski rak).
English: Progression-Free Survival Number of PFS Events (%) PFS Hazard Ratio (95% CI) and p-value
Croatian: Preživljenje bez progresije bolesti Broj događaja PFS-a (%) Omjer hazarda (95% CI) i p-vrijednost za PFS
English: Two clear type 1 glass pre-filled syringes with polystyrene plunger rod, fitted with a tamper-evident closure, each containing 5 ml Faslodex solution for injection.
Croatian: Dvije napunjene štrcaljke od prozirnog stakla tipa 1 s potisnim klipom od polistirena i sigurnosnim zatvaračem, od kojih svaka sadrži 5 ml Faslodex otopine za injekciju.
English: - The other ingredients (excipients) are ethanol (96 per cent), benzyl alcohol, benzyl benzoate and castor oil refined.
Croatian: - Drugi sastojci (pomoćne tvari) su etanol (96 postotni), benzilni alkohol, benzilbenzoat i rafinirano ricinusovo ulje.
English: Anaemia includes the following PTs: Anaemia, Haemoglobin decreased, Haematocrit decreased.
Croatian: Pojam „anemija“ obuhvaća sljedeće preporučene pojmove: anemiju, sniženu vrijednost hemoglobina, sniženu vrijednost hematokrita.
English: Ethanol (96 per cent), benzyl alcohol, benzyl benzoate and castor oil refined.
Croatian: Etanol (96 postotni), benzilni alkohol, benzilbenzoat i rafinirano ricinusovo ulje.
English: Faslodex 250 mg solution for injection.
Croatian: Faslodex 250 mg otopina za injekciju.
English: It has also been shown that fulvestrant 500 mg downregulates ER and the proliferation marker Ki67, to a greater degree than fulvestrant 250 mg in breast tumours in postmenopausal neoadjuvant setting.
Croatian: Pokazalo se također da u neoadjuvantnom liječenju tumora dojke u postmenopauzalnih žena fulvestrant u dozi od 500 mg snižava broj estrogenskih receptora i biljega proliferacije Ki67 u većoj mjeri nego fulvestrant u dozi od 250 mg.
English: Rash includes the following PTs: Rash, Rash maculo-papular, Rash pruritic, Rash erythematous, Rash papular, Dermatitis, Dermatitis acneiform, Toxic skin eruption.
Croatian: Pojam „osip“ obuhvaća sljedeće preporučene pojmove: osip, makulopapularni osip, pruritički osip, eritemski osip, papularni osip, dermatitis, akneiformni dermatitis, izbijanje kožnih promjena uzrokovanih toksičnim učinkom lijeka.
English: You must not breast-feed while on treatment with Faslodex.
Croatian: Tijekom liječenja lijekom Faslodex ne smijete dojiti.
English: Injection site related events including sciatica, neuralgia, neuropathic pain, and peripheral neuropathy have been reported with Faslodex injection.
Croatian: Kod primjene Faslodex injekcije, zabilježeni su događaji povezani s mjestom injiciranja uključujući išijas, neuralgiju, neuropatsku bol, i perifernu neuropatiju.
English: In patients administered Faslodex, an increase in exposure of this magnitude is expected to be well tolerated.
Croatian: Očekuje se da će bolesnice koje su primile Faslodex dobro podnijeti ovu razinu izloženosti.
English: Faslodex + Palbociclib (N=345)
Croatian: Faslodex + palbociklib (N=345)
English: was the primary endpoint; key secondary efficacy endpoints included objective response rate (ORR), clinical benefit rate (CBR) and overall survival (OS).
Croatian: Preživljenje bez progresije bolesti (PFS) bila je primarna mjera ishoda studije; ključne sekundarne mjere ishoda studije obuhvaćale su stopu objektivnog odgovora (ORR), stopu kliničke dobrobiti (CBR) i ukupno preživljenje (OS).
English: Caution should be taken while administering Faslodex at the dorsogluteal injection site due to the proximity of the underlying sciatic nerve (see sections 4.2 and
Croatian: Potreban je oprez pri primjeni lijeka Faslodex u dorzoglutealno mjesto injekcije zbog blizine ishijadičnog živca (vidjeti dijelove 4.2 i 4.8)
English: Adverse reactions listed below are classified according to frequency and System Organ Class (SOC).
Croatian: Navedene nuspojave klasificirane su prema učestalosti i klasifikaciji organskih sustava.
English: Neoadjuvant treatment for up to 16 weeks in breast cancer patients treated with either Faslodex 500 mg or Faslodex 250 mg did not result in clinically significant changes in endometrial thickness, indicating a lack of agonist effect.
Croatian: Neoadjuvantno liječenje tijekom najdulje 16 tjedana nije u bolesnica s rakom dojke liječenima lijekom Faslodex u dozi od 500 mg ili lijekom Faslodex u dozi od 250 mg dovelo do klinički značajnih promjena u debljini endometrija, što ukazuje da lijek nema agonistički učinak.
English: • Allergic (hypersensitivity) reactions, including swelling of the face, lips, tongue and/or throat that may be signs of anaphylactic reactions
Croatian: • alergijske reakcije (reakcije preosjetljivosti), uključujući oticanje lica, usana, jezika i/ili grla,
English: One clear type 1 glass pre-filled syringe with polystyrene plunger rod, fitted with a tamper-evident closure, containing 5 ml Faslodex solution for injection.
Croatian: Jedne napunjene štrcaljke od prozirnog stakla tipa 1 s potisnim klipom od polistirena i sigurnosnim zatvaračem, koja sadrži 5 ml Faslodex otopine za injekciju.
English: What Faslodex looks like and contents of the pack Faslodex is a clear, colourless to yellow, viscous solution in a pre-filled syringe fitted with a tamper-evident closure, containing 5 ml solution for injection.
Croatian: Faslodex je bistra, bezbojna do žuta, viskozna otopina u napunjenoj štrcaljki sa sigurnosnim zatvaračem, koja sadržava 5 ml otopine za injekciju.
English: Faslodex plus palbociclib (N=206)
Croatian: Faslodex plus palbociklib (N=206)
English: Faslodex plus palbociclib (N=141)
Croatian: Faslodex plus palbociklib (N=141)
English: • Pull shield straight off needle to avoid damaging needle point.
Croatian: • Povucite zaštitni zatvarač s igle ravno, kako ne biste oštetili vrh igle.
English: Faslodex 250 mg solution for injection fulvestrant
Croatian: Faslodex 250 mg otopina za injekciju fulvestrant
English: AstraZeneca AB, o.z.
Croatian: Slovenská republika AstraZeneca AB o.z.
English: In the FALCON study, the number of patients who reported an adverse reaction of joint and musculoskeletal pain was 65 (31.2%) and 48 (24.1%) for fulvestrant and anastrozole arms, respectively.
Croatian: Bol u zglobovima, mišićima i kostima je kao nuspojavu u ispitivanju FALCON prijavilo 65 (31,2%) bolesnica u skupini koja je primala fulvestrant i 48 (24,1%) onih u skupini koja je primala anastrozol.
English: All Patients -AE subgroup (n=423) -AI subgroup (n=313)
Croatian: Svi bolesnici -AE podskupina (n=423) -AI podskupina (n=313)
English: A Phase 3, international, randomised, double-blind, parallel-group, multicentre study of Faslodex 500 mg plus palbociclib 125 mg versus Faslodex 500 mg plus placebo was conducted in women with HR-positive, HER2-negative locally advanced breast cancer not amenable to resection or radiation therapy with curative intent or metastatic breast cancer, regardless of their menopausal status, whose disease progressed after prior endocrine therapy in the (neo) adjuvant or metastatic setting.
Croatian: od 125 mg uspoređivala s kombinacijom lijeka Faslodex u dozi od 500 mg i placeba u žena - neovisno o njihovu menopauzalnom statusu - s lokalno uznapredovalim HR-pozitivnim i HER2-negativnim rakom dojke koji se nije mogao kurativno liječiti resekcijom ni radioterapijom ili metastatskim rakom dojke, kojima je bolest uznapredovala nakon prethodne endokrine terapije u (neo)adjuvantnim ili metastatskim uvjetima.
English: Faslodex contains 10% w/v ethanol (alcohol) as an excipient, i.e. up to 500 mg per injection, equivalent to 10 ml beer or 4 ml wine.
Croatian: Kao pomoćnu tvar, Faslodex sadrži 10% m/V etanola (alkohol), odnosno do 500 mg po injekciji, što odgovara 10 ml piva ili 4 ml vina.
English: AstraZeneca A.E. Τηλ: + 30 210 6871500
Croatian: Τηλ: + 30 2 106871500
English: Faslodex contains 500 mg benzyl alcohol per injection, equivalent to 100 mg/ml.
Croatian: Jedna injekcija lijeka Faslodex sadrži 500 mg benzilnog alkohola, što odgovara količini od 100 mg/ml.
English: - previous problems with blood clots - osteoporosis (loss of bone density) - alcoholism
Croatian: - tegobe s bubrezima ili jetrom - nizak broj krvnih pločica (koje pomažu pri zgrušavanju krvi) ili poremećaji krvarenja - ranije tegobe s krvnim ugrušcima - osteoporoza (gubitak gustoće kostiju) - alkoholizam
English: Elevated hepatic enzymes (ALT, AST, ALP)
Croatian: Poremećaji jetre i žuči vrlo često povišene razine jetrenih enzima (ALT, AST, ALP)
English: Metabolism and nutrition disorders
Croatian: Poremećaji metabolizma i prehrane često anoreksija
English: All Patients -AE subgroup (n=423) -AI subgroup (n=313) OS
Croatian: Svi bolesnici -AE podskupina (n=423) -AI podskupina (n=313) OS
English: Patients with advanced/metastatic, symptomatic, visceral spread, that were at risk of life-threatening complications in the short term (including patients with
Croatian: U ispitivanju nisu mogle sudjelovati bolesnice s uznapredovalom/metastatskom i simptomatskom bolešću koja se proširila na visceralno tkivo, a u kojih je postojao rizik od po život opasnih komplikacija u kratkom roku (uključujući bolesnice s velikim nekontroliranim izljevima [pleuralnim, perikardijalnim, peritonealnim], plućnim limfangitisom i zahvaćenošću jetre većom od 50%).
English: Progression-Free Survival Median [months (95% CI)] Hazard ratio (95% CI) and p-value
Croatian: Medijan [mjeseci (95% CI)] Omjer hazarda (95% CI) i p-vrijednost
English: Ethanol (96 per cent) Benzyl alcohol Benzyl benzoate Castor oil refined
Croatian: 6.1 Popis pomoćnih tvari etanol (96 postotni) benzilni alkohol benzilbenzoat ricinusovo ulje, rafinirano
English: For the subgroup of patients with disease limited to non-visceral metastasis (n=208), the HR was 0.592 (95% CI: 0.419, 0.837) for the Faslodex arm compared to the anastrozole arm. For the subgroup of patients with visceral metastasis (n=254), the HR was 0.993 (95% CI: 0.740, 1.331) for the Faslodex arm compared to the anastrozole arm.
Croatian: U podskupini bolesnica s bolešću ograničenom na nevisceralne metastaze (n=208) HR za skupinu liječenu lijekom Faslodex u odnosu na onu koja je primala anastrozol iznosio je 0,592 (95% CI: 0,419; 0,837).
English: When Faslodex is combined with palbociclib, please also refer to the Summary of Product Characteristics of palbociclib.
Croatian: Kada se Faslodex kombinira s palbociklibom, vidjeti i sažetak opisa svojstava lijeka za palbociklib.
English: Blood and lymphatic system disorders
Croatian: Poremećaji krvi i limfnog sustava često smanjen broj trombocita
English: When Faslodex is used in combination with palbociclib, please also refer to the Summary of Product Characteristics of palbociclib.
Croatian: Kada se Faslodex primjenjuje u kombinaciji s palbociklibom, vidjeti i sažetak opisa svojstava lijeka za palbociklib.
English: Progression-free survival was the primary endpoint.
Croatian: Primarna mjera ishoda bila je preživljenje bez progresije bolesti.
English: Reproductive system and breast disorders
Croatian: Klasifikacija organskih sustava Učestalost
English: CBR Odds Ratio (95% CI) and p-value
Croatian: Omjer izgleda (95% CI) i p-vrijednost za CBR
English: Thrombocytopenia includes the following PTs: Thrombocytopenia, Platelet count decreased.
Croatian: Pojam „trombocitopenija“ obuhvaća sljedeće preporučene pojmove: trombocitopeniju, snižen broj trombocita.
English: • Parenteral solutions must be inspected visually for particulate matter and discolouration prior to administration.
Croatian: • Prije primjene, potrebno je pregledati parenteralnu otopinu da ne sadrži vidljive čestice i da nije promijenila boju.
English: Secondary end points* OR [% (95% CI)] OR (measurable disease) [% (95% CI)]
Croatian: Sekundarne mjere ishoda* OR [% (95% CI)]
English: ORR Odds Ratio (95% CI) and p-value
Croatian: Omjer izgleda (95% CI) i p-vrijednost za ORR
English: NOTE: Due to the proximity of the underlying sciatic nerve, caution should be taken if administering Faslodex at the dorsogluteal injection site (see section 4.4).
Croatian: Zbog blizine ishijadičnog živca, potreban je oprez ako se Faslodex primjenjuje na dorzoglutealnom mjestu injiciranja.
English: Crossover between treatment arms was not allowed.
Croatian: Nije bio dopušten prelazak iz jedne skupine u drugu.
English: Nausea
Croatian: pvrijednost
English: Vaginal moniliasis f, leukorrhea
Croatian: Poremećaji reproduktivnog sustava i dojki često vaginalno krvarenje manje često vaginalna monilijaza f, leukoreja
English: Tél/Tel: +32 2 370 48 11
Croatian: Luxembourg/Luxemburg NV AstraZeneca SA Tél/Tel: +32 2 370 48 11
English: • Expel excess gas from the syringe.
Croatian: • Istisnite suvišan zrak iz štrcaljke.
English: -AI subgroup (n=313) Variable
Croatian: Svi bolesnici -AE podskupina (n=423) -AI podskupina (n=313) Varijabla
English: Hepatic failure c, f
Croatian: često povišene razine bilirubina manje često zatajenje jetre c,f
English: Injection site haemorrhage f, injection site haematoma f, neuralgia c,f
Croatian: Opći poremećaji i reakcije na mjestu primjene vrlo često astenija a, reakcije na mjestu injekcije često periferna neuropatija e, išijas manje često krvarenje na mjestu injekcije f, hematom na mjestu injekcije f, neuralgija c,f
English: 800 mg/150 mg Film-coated tablet Oral use
Croatian: 800 mg/150 mg Filmom obložena tableta
English: Bottle (HDPE) 30 tablets
Croatian: Boca (HDPE)
English: Strength
Croatian: Kroz usta
English: Pack size
Croatian: PRILOG
English: This risk increases further:
Croatian: Rizik se dodatno povećava:
English: Venous thromboembolism can be fatal in 1-2% of cases.
Croatian: Venska tromboembolija može biti fatalna u 1-2% slučajeva.
English: Following a blood clot, recovery is not always complete.
Croatian: Nakon krvnog ugruška oporavak nije uvijek potpun.
English: Time to relieve of symptoms is at least three months.
Croatian: • Vrijeme potrebno za ublažavanje simptoma je najmanje tri mjeseca.
English: What < invented name > is and what it is used for
Croatian: Što je <zaštićeno ime> i za što se koristi
English: with increasing age; if you smoke.
Croatian: • ako pušite.
English: A full recovery is not always made and in 1-2% of cases, can be fatal.
Croatian: Do potpunog oporavka ne dolazi uvijek, a u 1-2 % slučajeva može doći do smrtnog ishoda.
English: [The wording below should be inserted in this section] When should you contact your doctor
Croatian: • [ Donji tekst mora se uvrstiti u ovaj dio] Kada morate kontaktirati Vašeg liječnika
English: Rarely serious permanent disabilities may occur or the blood clot may even be fatal.
Croatian: Rijetko može doći do trajne onesposobljenosti ili krvni ugrušak čak može biti fatalan.
English: Duration of Use
Croatian: • Trajanje uzimanja
English: In these situations it is advisable to discontinue use (in the case of elective surgery at least four weeks in advance) and not to resume until two weeks after complete remobilisation.
Croatian: U navedenim situacijama savjetuje se prekid primjene (u slučaju elektivne operacije najmanje četiri tjedna prije) i nastaviti s primjenom tek dva tjedna nakon potpune ponovne mobilnosti.
English: You and your doctor will have to consider all the things that would normally apply to the safe use of oral hormonal contraceptives
Croatian: Vi i Vaš doktor morat ćete uzeti u obzir sve stvari koje mogu uobičajeno utjecati na sigurnu primjenu hormonskih kontraceptiva.
English: Do not take <invented name>
Croatian: • Nemojte uzimati <zaštićeno ime>
English: The risk is not as high as the risk of developing a blood clot during pregnancy.
Croatian: Rizik je manji od rizika za nastanak krvnog ugruška tijekom trudnoće.
English: <invented name> also works as an oral contraceptive.
Croatian: • <Zaštićeno ime> također djeluje kao oralni kontraceptiv.
English: Due to its contraceptive properties it should only be prescribed for you if your doctor considers that treatment with a hormonal contraceptive is appropriate.
Croatian: Zbog svojih kontraceptivnih svojstava potrebno ga(ju) je propisati samo ako Vaš liječnik smatra da je liječenje hormonskim kontraceptivom prikladno.
English: If this applies to you, it is important to tell your doctor that you are using <invented name>, as the treatment may have to be stopped.
Croatian: Ako se ovo odnosi na Vas, važno je reći liječniku da koristite <zaštićeno ime>, jer će se liječenje možda morati prekinuti.
English: In the event of aggravation, exacerbation or first appearance of any of these conditions or risk factors, the woman should contact her physician.
Croatian: U slučaju pogoršanja, egzacerbacije ili prvoga pojavljivanja bilo kojeg od navedenih stanja ili faktora rizika, žena se treba javiti svom liječniku.
English: The symptoms are described in section 2 ‘Blood clots (Thrombosis)'.
Croatian: Simptomi su opisani u dijelu 2. ‘Krvni ugrušci (Tromboza)'.
English: The following serious adverse events have been reported in women using <invented name>, which are discussed in section 4.4 Special warning and precautions for use:
Croatian: • Sljedeći ozbiljni štetni događaji su prijavljeni u žena koje koriste <zaštićeno ime>, a koje su raspravljene u dijelu 4.4 Posebna upozorenja i mjere opreza pri uporabi:
English: Your doctor may tell you to stop using <invented name> several weeks before surgery or while you are less mobile.
Croatian: Liječnik Vam može reći da prestanete koristiti <zaštićeno ime> nekoliko tjedana prije operacije ili kada ste manje pokretni.
English: This can happen in veins of the leg, the lung (a lung embolus), or any other organ.
Croatian: To se može dogoditi u venama nogu, pluća (plućna embolija) ili bilo kojeg drugog organa.
English: For example, a blood clot in an artery in the heart may cause a heart attack, or in the brain may cause a stroke.
Croatian: Na primjer, krvni ugrušak u arteriji srca može uzrokovati srčani udar, ili u arteriji mozga moždani udar.
English: A blood clot in an artery can cause serious problems.
Croatian: Krvni ugrušak u arteriji može uzrokovati ozbiljne probleme.